In clinical trials, patients receiving MDMA therapy had reduced PTSD scores. Concerns arose about participants distinguishing between MDMA and placebo, affecting the drug's effectiveness.
"But the bigger question is what is the risk to those individuals?" - David Olson, Director of UC Davis Institute for Psychedelics and Neurotherapeutics, regarding the therapeutic use of MDMA for PTSD.
FDA staff raised concerns about the awareness of patients in trials, impacting the interpretation of the drug's efficacy. There is an unmet need for effective PTSD treatments.
[
add
]
[
|
|
...
]